Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.
To contribute published user compound and/or population files, upload your files here: Upload Model Files
http://onlinelibrary.wiley.com/doi/10.1002/cpt.750/full Ganciclovir compound file in healthy volunteers. Evaluation of the effect of renal impairment on the PK of OAT substrates. NOTE: Kp scaler in model should be 0.33, different from Table 1.
https://doi.org/10.1124/jpet.118.251413 Nicotine compound file with MechKiM
Metabolite of oseltamivir. Information can be found in Table 1 and supplemental file of the publication. Table 1. also in supplemental file. Correction: Molecular weight should be 284 g/mol (in cmp file). Table 1 mistakenly listed MW of prodrug oseltamivir. Correction will be submitted to journal. The submitted cmp file has custom dosing. Oral dosing should be selected and dose should be adjusted according to MW differences between OC and prodrug oseltamivir to allow OC PK to be simulated when prodrug is given intravenously.
The V23 Interleukin-6 (IL-6) research file has been developed as a therapeutic-protein modulator, acting as a suppressor of CYP1A2, CYP2C9, CYP2C19 and CYP3A4/5. The model has been verified against clinical data across a wide spectrum of IL-6 levels and various health conditions. The model has also been utilised to evaluate the time-course and magnitude of therapeutic protein-drug interaction during cytokine storm triggered infection and T-cell engager therapies.
|
27 |
> |
>| |